Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial (Q84574337)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 September 2009

Language	Label	Description	Also known as
English	Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial	scientific article published on 18 September 2009

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

phase III clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

object named as

Daisuke Aoki

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

8

object named as

Toru Sugiyama

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Noriyuki Katsumata

1

object named as

Noriyuki Katsumata

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Makoto Yasuda

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Fumiaki Takahashi

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Seiji Isonishi

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Toshiko Jobo

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Hiroshi Tsuda

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Shoji Kodama

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Eizo Kimura

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Kazunori Ochiai

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Kiichiro Noda

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Japanese Gynecologic Oncology Group

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

0 references

publication date

18 September 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

374

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

9698

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1331-1338

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Letter: Creatinine clearance: bedside estimate.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Theoretical concepts and the emerging role of taxanes in adjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961157-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)61157-0

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767092%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84574337&oldid=1822357071"